title: Biomarker and cytologic abnormalities in women at high and low risk for breast cancer.
abstract: Fine needle aspirates (FNA) from 106 high-risk women and 25 low-risk women were evaluated for overexpression of estrogen receptor (ER), epidermal growth factor receptor (EGFR), mutant p53, and HER-2/neu by immunocytochemistry, and for aneuploidy by image analysis. Aspirates were also classified cytologically as normal, apocrine metaplasia, epithelial hyperplasia (EH), or dysplasia. High-risk women were those with a first-degree relative with breast cancer (76%), precancerous breast disease (26%), prior cancer of the contralateral breast (9%), or multiple abnormalities (11%). Low-risk women had none of the above risk factors, nor a prior breast biopsy or clinical evidence of fibrocystic disease. The median 10-year Gail risk for the high-risk group was 4%, compared to 0.7% for the low-risk group. There were significant differences (p < 0.01) between high- and low-risk women in the prevalences of hyperplasia (55% versus 12%), dysplasia (19% versus 0%), aneuploidy (32% versus 0%), overexpressed EGFR (32% versus 4%), and overexpressed p53 (29% versus 4%). The prevalence of multiple biomarker abnormalities was also greater in high-risk than in low-risk women (28% versus 0%; p < 0.01). Four percent (4%) of FNAs from high-risk women with normal cytology, 29% of aspirates with hyperplastic cytology, and 60% of those with dysplasia were associated with two or more biomarker abnormalities. The differences in the prevalence of multiple biomarker abnormalities among various cytologic categories were statistically significant (p = 0.02, normal versus EH; p = 0.02, EH versus dysplasia; p < 0.01, normal versus dysplasia).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: University of Kansas Cancer Center, Kansas City 66160.
authors.forename: C J
authors.initials: CJ
authors.lastname: Fabian
authors.forename: C
authors.initials: C
authors.lastname: Zalles
authors.forename: S
authors.initials: S
authors.lastname: Kamel
authors.forename: R
authors.initials: R
authors.lastname: McKittrick
authors.forename: W P
authors.initials: WP
authors.lastname: Moore
authors.forename: S
authors.initials: S
authors.lastname: Zeiger
authors.forename: C
authors.initials: C
authors.lastname: Simon
authors.forename: B
authors.initials: B
authors.lastname: Kimler
authors.forename: A
authors.initials: A
authors.lastname: Cramer
authors.forename: F
authors.initials: F
authors.lastname: Garcia
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D016158:Genes, p53; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008875:Middle Aged; D010865:Pilot Projects; D011003:Ploidies; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen / Q000378:metabolism; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen